Navigation Links
Edison Pharma Hits Milestone as A0001 Enters Phase 1 Clinical Development
Date:7/14/2008

Targeting inherited mitochondrial diseases as an archetype for diseases of

aging

SAN JOSE, Calif., July 15 /PRNewswire/ -- Edison Pharmaceuticals, Inc., a privately held biotechnology company located in San Jose, CA, announced today that EPI-A0001 (A0001) has entered clinical development, triggering a milestone payment from Penwest Pharmaceuticals, Edison's development partner. Penwest has begun dosing in a Phase 1a clinical trial of A0001, a 2nd generation coenzyme Q10 (CoQ10) analog. It differs from CoQ10 in that it possesses more favorable oral absorption and electron transfer properties.

CoQ10 is a first-line therapy for many rare diseases of energy metabolism. Efforts to improve CoQ10 have centered on improving its oral absorption properties. Edison's focus is on building next-generation CoQ10 analogs through improving its electron transfer, otherwise known as redox, properties. Edison is a leader in the design and development of redox drugs.

Edison's initial therapeutic focus is on rare inherited mitochondrial diseases. Today, there are no FDA- approved treatments for these diseases. CoQ10, and closely related analogs, have been deployed with real, but limited clinical results. Edison's strategy is to improve upon CoQ10's biological activity by optimizing its redox properties. A0001 is the first redox-optimized CoQ10 analog in Edison's clinical development pipeline.

Edison's technical focus is on redox drugs targeting metabolic control and energy metabolism. Children with inherited mitochondrial defects clinically present with many conditions commonly associated with aging. Edison believes that inherited mitochondrial diseases may be genetic roadmaps to deciphering the biochemical basis of metabolic control and aging. Given CoQ10's known role in mitochondrial disease and aging, as well as its redox activity, Edison's initial investigations are focusing on the development of CoQ10 based drugs.

"Today we have reached a key milestone in transforming Edison from a discovery to development-stage company," stated Guy Miller, M.D., Ph.D., Chairman and CEO of Edison. "A0001's entry into Phase 1 is the first step in validating Edison's platform and providing needed therapies for patients suffering from rare mitochondrial diseases. As we look toward the future, we expect to focus our energies on refining our approach to treating rare mitochondrial diseases, and expanding our investigation of redox drugs for the treatment of diseases of aging."

About Edison Pharmaceuticals

Edison Pharmaceuticals, Inc. is a biotechnology company based in Silicon Valley California at the San Jose Biocenter with a specialized knowledge in redox biochemistry and drug design. The company is focused on developing drugs for rare mitochondrial diseases that impair energy metabolism, for which there are no FDA-approved treatments. Edison is leveraging its skills in redox biology and chemistry, and data obtained in its inherited mitochondrial disease programs, to discover new therapeutics for diseases commonly associated with aging.


'/>"/>
SOURCE Edison Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine
2. VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial
3. Cerimon Pharmaceuticals Initiates Phase II Study to Evaluate Simulect(R) (Basiliximab) for Noninfectious Uveitis
4. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
5. McGraw-Hill Professional Launches Drug Effectiveness Resource on AccessPharmacy
6. Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
7. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
8. University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society
9. Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
10. IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following June Meeting of European Committee for Medicinal Products for Human Use (CHMP)
11. Isis Pharmaceuticals Conference Call Notice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... LONDON , February 10, 2016 A new report ... 2021 - states that the Alzheimer,s disease market will more than double ... 2021, at a Compound Annual Growth Rate (CAGR) of 11%. ... Italy , Spain , the UK, and ... prevalence during the forecast period. --> Canada , ...
(Date:2/10/2016)... SAN DIEGO , Feb. 10, 2016 ... viral gene therapy manufacturing, and Renova™ Therapeutics, a biopharmaceutical ... and other chronic diseases, have entered into a Manufacturing ... produce cGMP-grade RT-100 (Ad5.hAC6) Drug Product for use in ... --> This relationship will leverage Lonza,s ...
(Date:2/10/2016)... , Feb. 10, 2016 Immune Pharmaceuticals Inc. ... announced today that it has filed a patent application ... other cancers. --> --> ... by administration of Ceplene (histamine dihydrochloride) in combination with ... of predicting the efficacy of Ceplene and IL-2 therapy ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... Intermedix ... of Emergency Medicine , an emergency medicine professional association, to support the organization's ... , The American Academy of Emergency Medicine, or AAEM, seeks to empower emergency ...
(Date:2/10/2016)... , ... February 10, 2016 , ... Emergency rooms provide ... to find. Unfortunately, this can leave patients with dental emergencies at risk of losing ... now offering emergency dental care. , Common dental emergencies include:, ...
(Date:2/10/2016)... ... February 10, 2016 , ... Dr. Jessica Barron, of ... is now accepting new dental patients and families in the North Metro Denver area. ... services from cleanings to cosmetic dentistry, and all in the most relaxing environment. , ...
(Date:2/10/2016)... , ... February 10, 2016 , ... ... organization, welcomes S.S. Nesbitt as the latest addition to its growing list of ... other locations throughout the Southeast, from Orlando to Huntsville and in between. , ...
(Date:2/10/2016)... ... , ... Armune BioScience signed a definitive agreement with ARCpoint ... across the country. Launched in April of 2015, Apifiny is the only cancer specific, ... order volume exceeded 3,000 tests in 2015. Primary care physicians and urologists have utilized ...
Breaking Medicine News(10 mins):